Research on Multiperson Motion Capture System Combining Target Positioning and Inertial Attitude Sensing Technology

The purpose of this study is to solve the problems of multiple targets, poor accuracy, and inability to obtain displacement information in motion capture. Based on fusion target positioning and inertial attitude sensing technology, Unity3D is employed to create 3D scenes and 3D human body models to read real-time raw data from inertial sensors. Furthermore, a gesture fusion algorithm is used to process the raw data in real time to generate a quaternion, and a human motion capture system is designed based on inertial sensors for the complete movement information recording of the capture target. Results demonstrate that the developed system can accurately capture multiple moving targets and provide a higher recognition rate, reaching 75%∼100%. The maximum error of the system adopting the fusion target positioning algorithm is 10 cm, a reduction of 71.24% compared with that not using the fusion algorithm. The movements of different body parts are analyzed through example data. The recognition efficiency of “wave,” “crossover,” “pick things up,” “walk,” and “squat down” is as high as 100%. Hence, the proposed multiperson motion capture system that combines target positioning and inertial attitude sensing technology can provide better performance. The results are of great significance to promote the development of industries such as animation, medical care, games, and sports training.

Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity

ASH1L histone methyltransferase plays a crucial role in the pathogenesis of different diseases, including acute leukemia. While ASH1L represents an attractive drug target, developing ASH1L inhibitors is challenging, as the catalytic SET domain adapts an inactive conformation with autoinhibitory loop blocking the access to the active site. Here, by applying fragment-based screening followed by medicinal chemistry and a structure-based design, we developed first-in-class small molecule inhibitors of the ASH1L SET domain. The crystal structures of ASH1L-inhibitor complexes reveal compound binding to the autoinhibitory loop region in the SET domain. When tested in MLL leukemia models, our lead compound, AS-99, blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo. This work validates the ASH1L SET domain as a druggable target and provides a chemical probe to further study the biological functions of ASH1L as well as to develop therapeutic agents.